

Docket No.: CRP-059CP
(2054/28)

jc531 U.S. PTO
09/597517
06/20/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Kuberasampath et al.

SERIAL NO.: 07/938,336

FILED : August 28, 1992

TITLE : MORPHOGEN-INDUCED MODULATION OF
INFLAMMATORY RESPONSE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: The Honorable Commissioner of Patents and Trademarks, Washington, D.C. 20231 on January 22, 1993.

Michelle A. LaPlume
Michelle A. LaPlume

The Honorable Commissioner
of Patents and Trademarks
Washington, D.C. 20231


Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. §1.97, Applicants hereby make of record the following information and publications which have been identified in, or reviewed during the preparation of the above-referenced patent application. Copies of PTO Form 1449 and each publication listed thereon, U.S. Patents AA-AI, foreign patent documents BA-BG, and references CA-CZ, accompany this statement.

Please charge any fees associated with the submission of this Information Disclosure Statement and accompanying 1449 Form to Deposit Account No. 20-0531.

Respectfully submitted,


Madeline I. Johnston, Ph.D.
Reg. No. 36,174
Agent for Applicants

Dated: January 22, 1993

TESTA, HURWITZ & THIBEAULT
Exchange Place
53 State Street
Boston, MA 02109
617/248-7316

Atty. Docket No.: CRP-059CP (2054/28)

JC531 U.S. PTO
09/597517
06/20/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Kuberasampath et al.

SERIAL NO.: 07/938,336

FILED: August 28, 1992

TITLE: MORPHOGEN-INDUCED MODULATION OF INFLAMMATORY RESPONSE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First-Class Mail, postage prepaid, in an envelope addressed to the: Honorable Commissioner of Patents and Trademarks, Washington, D.C. on February 11, 1993.

Robin E. Bolduc
Robin E. Bolduc

Honorable Commissioner of Patents
& Trademarks
Washington, D.C. 20231

Supplemental Information Disclosure Statement

In accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, copies of the seven references listed on the accompanying PTO-1449 forms are enclosed and the following certification is made.


It is hereby certified pursuant to Rule 1.97 (c)(2) and (e)(1) that the seven references contained in this supplemental information disclosure statement (SIDS) were cited in a communication (copy enclosed) from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this SIDS.

Note that the last two references listed on the communication from the foreign patent office (namely, WO 89/09788 and Ozkaynak et al., Embo J., 9:2085-2093, 1990) are not included in this SIDS because they were cited (as items BE and CM) in an IDS mailed on January 22, 1993 for the above-identified case.


A check is not enclosed because it is believed no fee is required. If a fee is connected with this filing, please charge our Deposit Account No. 20-0531.

Respectfully submitted,

Date: February 11, 1993



Robin D. Kelley
Agent for Applicants
Registration No. 34,637



Testa, Hurwitz & Thibault
Exchange Place, 53 State Street
Boston, MA 02109
(617) 248-7477

295RJT2054.AB2

Att'y. Docket No. CRP-059CPFW
(2054/28)

PATENT
09/597517
06/20/00



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Kuberasampath et al.

FWC of
SERIAL NUMBER: 08/165,511 GROUP NUMBER: 1805

FILING DATE: Herewith EXAMINER: P. Carter

TITLE: MORPHOGEN-INDUCED MODULATION OF INFLAMMATORY
RESPONSE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service via Express Mail, Mailing Label No. TB576901941US, postage prepaid, in an envelope addressed to: The Honorable Commissioner of Patents and Trademarks, Washington D.C., 20231 on May 22, 1995.

Date:

May 22, 1995

Melanie Smith
Melanie Smith

INFORMATION DISCLOSURE STATEMENT

The Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §§ 1.97 and 1.98, Applicants submit the instant Information Disclosure Statement and PTO Form 1449 for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patent documents and references are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **Filing Date** or before the mailing date of the **First Office Action** on the merits; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **Final Rejection** or **Notice of Allowance**, and
- ☐ the requisite Certification is attached hereto, **OR**
- ☐ the requisite fee under Rule 1.17(p), namely **\$210.00**, is included herein, or
- ☐ (3) after the mailing date of a **Final Rejection** or **Notice of Allowance** but before the payment of the **Issue Fee**, **AND**
- ☐ Applicant hereby petitions the Commissioner to accept and consider the attached Information Disclosure Statement, **AND**
- ☐ the requisite Certification, is attached hereto, **AND**
- ☐ the requisite petition fee due under Rule 1.17(i)(I), namely **\$130.00** is included herein.

It is respectfully requested that each of the documents shown on the attached form PTO-1449 be made of record in this application.


CERTIFICATION

As required under §1.97(e), Applicants, through the undersigned, hereby certify either that [check the appropriate space]:

- ☐ 1. [E]ach item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application **not more than** three months prior to the filing date of the Statement; or
- ☐ 2. [N]o item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing this Certification after making reasonable inquiry, was known to any individual designated in §1.56(c) **more than** three months prior to the filing of the Statement.

FEE AUTHORIZATION

Should any fee associated with the submission of this paper not be attached hereto as a check, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 20-0531. Any overpayments should be credited to said Deposit Account.


Gillian M. Fenton
Attorney for Applicants
Reg. No. 36,508

Date: 5/22/15

Testa, Hurwitz, & Thibault
Exchange Place
53 State Street
Boston, Massachusetts 02109

Tel: (617) 248-7560

254GMF2054/28.88322_1

Atty. Docket No. CRP-059CPFW
(2054/28)

PATENT
Jc531 U.S. PTO
09/597517
06/20/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Kuberasampath et al.

SERIAL NUMBER:

08/445,467

GROUP NUMBER:

1801

FILING DATE:

May 22, 1995

EXAMINER:

E. Kemmerer

TITLE:

MORPHOGEN-INDUCED MODULATION OF INFLAMMATORY
RESPONSE

CERTIFICATE OF HAND-DELIVERY

I hereby certify that this correspondence and any document referred to as being attached hereto is being hand-delivered to: Group 1801, Assistant Commissioner for Patents, Washington D.C., 20231 on _____.

Date: _____

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §§ 1.97 and 1.98, Applicants submit the instant Supplemental Information Disclosure Statement and PTO Form 1449 for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patent documents and references are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed (CHECK ONE):



(1) within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits; or

- ☒ (2) after the period defined in (1) but before the mailing date of a **Final Rejection** or **Notice of Allowance**, and
- ☐ the requisite Certification is attached hereto, **OR**
- ☒ the requisite fee under Rule 1.17(p), namely **\$230.00**, is included herein, or
- ☐ (3) after the mailing date of a **Final Rejection** or **Notice of Allowance** but before the payment of the **Issue Fee**, **AND**
- ☐ Applicant hereby petitions the Commissioner to accept and consider the attached Information Disclosure Statement, **AND**
- ☐ the requisite Certification, is attached hereto, **AND**
- ☐ the requisite petition fee due under Rule 1.17(i)(I), namely **\$130.00** is included herein.

It is respectfully requested that each of the documents shown on the attached form PTO-1449 be made of record in this application.


CERTIFICATION

As required under §1.97(e), Applicants, through the undersigned, hereby certify either that [check the appropriate space]:

- ☐ 1. [E]ach item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of the Statement; or
- ☐ 2. [N]o item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing this Certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

FEE AUTHORIZATION

Should any fee associated with the submission of this paper not be attached hereto as a check, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 20-0531. Any overpayments should be credited to said Deposit Account.


Gillian M. Fenton
Attorney for Applicants
Reg. No. 36,508

Date:

27 August, 1997

Testa, Hurwitz, & Thibault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110

Tel: (617) 248-7560

254GMF2054/28.403002_1